Neoadjuvant therapy for pancreatic ductal adenocarcinoma: Opportunities for personalized cancer care

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy that is best treated in a multidisciplinary fashion using surgery, chemotherapy, and radiation. Adjuvant chemotherapy has shown to have a significant survival benefit in patients with resected PDAC. However, up to 50% of patients fa...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamad, Ahmad, Brown, Zachary J, Ejaz, Aslam M, Dillhoff, Mary, Cloyd, Jordan M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Minireviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8316910/
https://www.ncbi.nlm.nih.gov/pubmed/34366611
http://dx.doi.org/10.3748/wjg.v27.i27.4383

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8316910/
https://www.ncbi.nlm.nih.gov/pubmed/34366611
http://dx.doi.org/10.3748/wjg.v27.i27.4383

Ejemplares similares